US › Healthcare

Caribou Biosciences Inc (CRBU)

US · Healthcare · Biotechnology

$1.31+4.80%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$1.5M

Revenue YoY

-43.8%

Net profit

$-24.3M

EPS

$-0.24

EPS estimate

$-0.33

Net margin

-1,619.9%

EPS came in at -0.24 against a street estimate of -0.33 — a beat of 27.3%.

Key statistics

Market cap

$136.2M

Forward P/E

0.0

P/B

1.40

Book value

$0.93

EPS (TTM)

$-1.08

52-week high

$3.54

52-week low

$1.26

50-day MA

$1.63

200-day MA

$1.78

Beta

2.28

Analyst view

Analysts rate Caribou Biosciences Inc a buy (7 buy, 2 hold, 0 sell out of 9) with an average price target of $11.86.

Shareholding

Insiders

8.24%

Institutions

44.85%

Largest institutional holders

Fund	Stake
Pfizer Inc	4.38%
Vanguard Capital Management, LLC	3.51%
Renaissance Technologies Corp	2.42%
Kynam Capital Management, LP	2.33%
BlackRock Inc	2.00%
Bank of America Corp	1.21%
Marshall Wace Asset Management Ltd	1.12%
Two Sigma Investments LLC	0.98%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Caribou Biosciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.